Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG"...
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated,...
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting
SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd....
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001,...